Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: A Children's Oncology Group report

S. Goldman, L. Smith, J. R. Anderson, S. Perkins, L. Harrison, M. B. Geyer, T. G. Gross, H. Weinstein, S. Bergeron, B. Shiramizu, W. Sanger, M. Barth, J. Zhi, M. S. Cairo

Research output: Contribution to journalLetter

85 Scopus citations
Original languageEnglish (US)
Pages (from-to)1174-1177
Number of pages4
JournalLeukemia
Volume27
Issue number5
DOIs
StatePublished - May 2013

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Goldman, S., Smith, L., Anderson, J. R., Perkins, S., Harrison, L., Geyer, M. B., Gross, T. G., Weinstein, H., Bergeron, S., Shiramizu, B., Sanger, W., Barth, M., Zhi, J., & Cairo, M. S. (2013). Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: A Children's Oncology Group report. Leukemia, 27(5), 1174-1177. https://doi.org/10.1038/leu.2012.255